当前位置: X-MOL 学术Eur. Heart J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
European Heart Journal ( IF 39.3 ) Pub Date : 2018-03-07 , DOI: 10.1093/eurheartj/ehy060
Mintu P Turakhia 1 , Peter J Blankestijn 2 , Juan-Jesus Carrero 3 , Catherine M Clase 4 , Rajat Deo 5 , Charles A Herzog 6 , Scott E Kasner 7 , Rod S Passman 8 , Roberto Pecoits-Filho 9 , Holger Reinecke 10 , Gautam R Shroff 11 , Wojciech Zareba 12 , Michael Cheung 13 , David C Wheeler 14 , Wolfgang C Winkelmayer 15 , Christoph Wanner 16 , Kerstin Amann , Debasish Banerjee , Nisha Bansal , Giuseppe Boriani , Jared Bunch , Christopher T Chan , David M Charytan , David Conen , Allon N Friedman , Simonetta Genovesi , Rachel M Holden , Andrew A House , Michel Jadoul , Alan G Jardine , David W Johnson , Min Jun , Laura Labriola , Patrick B Mark , Peter A McCullough , Thomas D Nolin , Tatjana S Potpara , Patrick H Pun , Antonio L P Ribeiro , Patrick Rossignol , Jenny I Shen , Manish M Sood , Yusuke Tsukamoto , Angela Yee-Moon Wang , Matthew R Weir , James B Wetmore , Jerzy K Wranicz , Hiro Yamasaki ,
Affiliation  

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders, including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular arrhythmias, and sudden cardiac death (SCD). While treatment options, including drug, device, and procedural therapies, are available, their use in the setting of CKD is complex and limited. Patients with CKD and end-stage kidney disease (ESKD) have historically been under-represented or excluded from randomized trials of arrhythmia treatment strategies,1 although this situation is changing.2 Cardiovascular society consensus documents have recently identified evidence gaps for treating patients with CKD and heart rhythm disorders.3–7 To identify key issues relevant to the optimal prevention, management, and treatment of arrhythmias and their complications in patients with kidney disease, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference in Berlin, Germany, titled CKD and Arrhythmias in October 2016. The conference agenda and discussion questions are available on the KDIGO website (http://kdigo.org/conferences/ckd-arrhythmias/; 13 February 2018).

中文翻译:

慢性肾脏病和心律失常:来自肾脏疾病的结论:改善全球结果 (KDIGO) 争议会议

慢性肾脏病 (CKD) 患者易患心律失常,包括心房颤动 (AF)/心房扑动、室上性心动过速、室性心律失常和心源性猝死 (SCD)。尽管有多种治疗选择,包括药物、器械和程序疗法,但它们在 CKD 环境中的应用是复杂且有限的。CKD 和终末期肾病 (ESKD) 患者历来在心律失常治疗策略的随机试验中代表性不足或被排除在外,1 尽管这种情况正在改变。 2 心血管学会共识文件最近确定了治疗 CKD 患者的证据差距3–7 确定与最佳预防、管理、
更新日期:2018-03-07
down
wechat
bug